Company CEO Stepping Up in Shutting down Short Sel
Post# of 25429
(Total Views: 268)
Posted On: 11/23/2022 5:41:03 AM
Company CEO Stepping Up in Shutting down Short Sellers and Hedge Funds
CEO of Regencell Bioscience Holdings has voiced out against traders who are shorting and putting out negative schemes on the company stock, negatively impacting the company’s image.
Regencell Bioscience Holdings (RGC: Nasdaq) is a an early-staged bioscience healthcare company focusing on R&D and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degenerations.
These negative schemes have indirectly put harm to RGC investors and patients whom rely on the company’s developments to develop a natural approach towards treatment of Attention Hyperactive Disorder (ADHD) Autism Spectrum Disorder (ASD) and Covid-19.
RGC’s CEO (Mr Yat-Gai Au) has agreed to continue draw 1$ annual salary and with no bonuses until the company has reached $1 Billion market cap and reserve share options for all employees except himself. He has even pledged to continue putting personal funds to buyback company shares to display his commitment to the company and his stances against short sellers.
More so, to further demonstrate the company’s commitment, all directors and employees who were granted with stock options during IPO have agreed to a 6 months lockup after it is vested. These stocks options will be vested on July 16th 2022, hence it will remain locked until Janurary 16th 2023.
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]
CEO of Regencell Bioscience Holdings has voiced out against traders who are shorting and putting out negative schemes on the company stock, negatively impacting the company’s image.
Regencell Bioscience Holdings (RGC: Nasdaq) is a an early-staged bioscience healthcare company focusing on R&D and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degenerations.
These negative schemes have indirectly put harm to RGC investors and patients whom rely on the company’s developments to develop a natural approach towards treatment of Attention Hyperactive Disorder (ADHD) Autism Spectrum Disorder (ASD) and Covid-19.
RGC’s CEO (Mr Yat-Gai Au) has agreed to continue draw 1$ annual salary and with no bonuses until the company has reached $1 Billion market cap and reserve share options for all employees except himself. He has even pledged to continue putting personal funds to buyback company shares to display his commitment to the company and his stances against short sellers.
More so, to further demonstrate the company’s commitment, all directors and employees who were granted with stock options during IPO have agreed to a 6 months lockup after it is vested. These stocks options will be vested on July 16th 2022, hence it will remain locked until Janurary 16th 2023.
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]
(0)
(0)